Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) Return on Capital Employed: 2020-2025

Historic Return on Capital Employed for Avidity Biosciences (RNA) over the last 5 years, with Sep 2025 value amounting to -0.39%.

  • Avidity Biosciences' Return on Capital Employed fell 16.00% to -0.39% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.39%, marking a year-over-year decrease of 16.00%. This contributed to the annual value of -0.38% for FY2024, which is 5.00% up from last year.
  • Avidity Biosciences' Return on Capital Employed amounted to -0.39% in Q3 2025, which was up 5.09% from -0.41% recorded in Q2 2025.
  • Over the past 5 years, Avidity Biosciences' Return on Capital Employed peaked at -0.20% during Q1 2021, and registered a low of -0.45% during Q4 2023.
  • For the 3-year period, Avidity Biosciences' Return on Capital Employed averaged around -0.34%, with its median value being -0.36% (2024).
  • As far as peak fluctuations go, Avidity Biosciences' Return on Capital Employed fell by 18bps in 2021, and later grew by 20bps in 2024.
  • Over the past 5 years, Avidity Biosciences' Return on Capital Employed (Quarterly) stood at -0.30% in 2021, then declined by 7bps to -0.37% in 2022, then decreased by 8bps to -0.45% in 2023, then climbed by 20bps to -0.25% in 2024, then dropped by 16bps to -0.39% in 2025.
  • Its last three reported values are -0.39% in Q3 2025, -0.41% for Q2 2025, and -0.30% during Q1 2025.